Inhibition of human matriptase by eglin c variants

FEBS Letters

Volumn 580, Issue 9, 2006, Pages 2227-2232

  Désilets, Antoine ^a   Longpré, Jean Michel ^a   Beaulieu, Marie Ève ^a   Leduc, Richard ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Eglin c; Enzyme inhibition; Matriptase; Serine protease

Indexed keywords

ARGININE; COMPLEMENTARY DNA; EGLIN C; LYSINE; MATRIPTASE; MEMBRANE PROTEIN; PROLINE; PROTEINASE INHIBITOR; SERINE PROTEINASE; TYROSINE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA LIBRARY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EPITHELIUM TUMOR; ESCHERICHIA COLI; GENE OVEREXPRESSION; GENETIC SCREENING; GENETIC VARIABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; QUANTUM YIELD; WILD TYPE;

ESCHERICHIA COLI;

EID: 33645976804     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.03.030     Document Type: Article

References (33)

1. Takeuchi T., Shuman M.A., and Craik C.S. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 96 (1999) 11054-11061
2. List K., et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21 (2002) 3765-3779
3. Lee S.L., Dickson R.B., and Lin C.Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275 (2000) 36720-36725
4. Takeuchi T., Harris J.L., Huang W., Yan K.W., Coughlin S.R., and Craik C.S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275 (2000) 26333-26342
5. Suzuki M., Kobayashi H., Kanayama N., Saga Y., Lin C.Y., Dickson R.B., and Terao T. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J. Biol. Chem. 279 (2004) 14899-14908
6. Kang J.Y., Dolled-Filhart M., Ocal I.T., Singh B., Lin C.Y., Dickson R.B., Rimm D.L., and Camp R.L. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63 (2003) 1101-1105
7. Oberst M.D., et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8 (2002) 1101-1107
8. Forbs D., Thiel S., Stella M.C., Sturzebecher A., Schweinitz A., Steinmetzer T., Sturzebecher J., and Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int. J. Oncol. 27 (2005) 1061-1070
9. List K., et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 19 (2005) 1934-1950
10. Vaarala M.H., Porvari K., Kyllonen A., Lukkarinen O., and Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer 94 (2001) 705-710
11. Sawasaki T., Shigemasa K., Gu L., Beard J.B., and O'Brien T.J. The transmembrane protease serine (TMPRSS3/TADG-12) D variant: a potential candidate for diagnosis and therapeutic intervention in ovarian cancer. Tumour Biol. 25 (2004) 141-148
12. Klezovitch O., Chevillet J., Mirosevich J., Roberts R.L., Matusik R.J., and Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6 (2004) 185-195
13. Bergeron F., Leduc R., and Day R. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J. Mol. Endocrinol. 24 (2000) 1-22
14. Komiyama T., and Fuller R.S. Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin. Biochemistry 39 (2000) 15156-15165
15. Liu Z.X., Fei H., and Chi C.W. Two engineered eglin c mutants potently and selectively inhibiting kexin or furin. FEBS Lett. 556 (2004) 116-120
16. Komiyama T., VanderLugt B., Fugere M., Day R., Kaufman R.J., and Fuller R.S. Optimization of protease-inhibitor interactions by randomizing adventitious contacts. Proc. Natl. Acad. Sci. USA 100 (2003) 8205-8210
17. Molloy S.S., Bresnahan P.A., Leppla S.H., Klimpel K.R., and Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J. Biol. Chem. 267 (1992) 16396-16402
18. Denault J.B., Lazure C., Day R., and Leduc R. Comparative characterization of two forms of recombinant human SPC1 secreted from Schneider 2 cells. Protein Expr. Purif. 19 (2000) 113-124
19. Bieth J.G. Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol. 248 (1995) 59-84
20. Carson M. Ribbons. Methods Enzymol. 277 (1997) 493-502
21. Schechter I., and Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27 (1967) 157-162
22. Chokki M., Yamamura S., Eguchi H., Masegi T., Horiuchi H., Tanabe H., Kamimura T., and Yasuoka S. Human airway trypsin-like protease increases mucin gene expression in airway epithelial cells. Am. J. Respir. Cell. Mol. Biol. 30 (2004) 470-478
23. Baici A., and Seemuller U. Kinetics of the inhibition of human leucocyte elastase by eglin from the leech Hirudo medicinalis. Biochem. J. 218 (1984) 829-833
24. Ascenzi P., Amiconi G., Menegatti E., Guarneri M., Bolognesi M., and Schnebli H.P. Binding of the recombinant proteinase inhibitor eglin c from leech Hirudo medicinalis to human leukocyte elastase, bovine alpha-chymotrypsin and subtilisin Carlsberg: thermodynamic study. J. Enzyme Inhib. 2 (1988) 167-172
25. Heinz D.W., Hyberts S.G., Peng J.W., Priestle J.P., Wagner G., and Grutter M.G. Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation. Biochemistry 31 (1992) 8755-8766
26. Fei H., Luo M.J., Ye Y.Z., Ding D.F., and Chi C.W. The inhibitory activities of recombinant eglin C mutants on kexin and furin, using site-directed mutagenesis and molecular modeling. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 33 (2001) 591-599
27. Li A., and Daggett V. Investigation of the solution structure of chymotrypsin inhibitor 2 using molecular dynamics: comparison to X-ray crystallographic and NMR data. Protein Eng. 8 (1995) 1117-1128
28. Hyberts S.G., Goldberg M.S., Havel T.F., and Wagner G. The solution structure of eglin c based on measurements of many NOEs and coupling constants and its comparison with X-ray structures. Protein Sci. 1 (1992) 736-751
29. Friedrich R., et al. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem. 277 (2002) 2160-2168
30. Galkin A.V., Mullen L., Fox W.D., Brown J., Duncan D., Moreno O., Madison E.L., and Agus D.B. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 61 (2004) 228-235
31. Enyedy I.J., Lee S.L., Kuo A.H., Dickson R.B., Lin C.Y., and Wang S. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J. Med. Chem. 44 (2001) 1349-1355
32. Stoop A.A., and Craik C.S. Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nat. Biotechnol. 21 (2003) 1063-1068
33. Sun J., Pons J., and Craik C.S. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 42 (2003) 892-900